Oophorectomy - What is screening?
Screening is looking for cancer before a person has any symptoms. This can help find cancer at an early stage. When abnormal tissue or cancer is found early,it may be easier to treat. By the time symptoms appear,cancer may have begun to spread. Scientists are trying to better understand which people are more likely to get certain types of cancer. They also study the things we do and the ...
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Changes to This Summary (06 / 12 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Editorial changes were made to this summary.
Oophorectomy - Early-Stage Ovarian Low Malignant Potential Tumors
The value of complete staging has not been demonstrated for early-stage cases, but the opposite ovary should be carefully evaluated for evidence of bilateral disease. Although the impact of surgical staging on therapeutic management is not defined, in a study, 7 of 27 patients with presumed localized disease were upstaged following complete surgical staging. In two other studies, 16% and 18% of patients with presumed localized tumors of low malignant potential were upstaged as a result of a staging laparotomy.[2,3] In one of these studies, the yield for serous tumors was 30.8% compared with 0% for mucinous tumors. In another study, patients with localized intraperitoneal disease and negative lymph nodes had a low incidence of recurrence (5%), whereas patients with localized intraperitoneal disease and positive lymph nodes had a statistically significantly higher incidence of recurrence (50%).In early-stage disease (stage I or II), no additional treatment is indicated for a
Oophorectomy - To Learn More About Ovarian Low Malignant Potential Tumors
For general cancer information and other resources from the National Cancer Institute, see the following:What You Need to Know About™ CancerUnderstanding Cancer Series: CancerCancer StagingChemotherapy and You: Support for People With CancerRadiation Therapy and You: Support for People With CancerCoping with Cancer: Supportive and Palliative CareQuestions to Ask Your Doctor About CancerCancer LibraryInformation For Survivors/Caregivers/Advocates
Ovarian Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Overview
Incidence and Mortality In 2013, it is estimated that 22,240 new cases of ovarian cancer will be diagnosed and 14,030 deaths due to ovarian cancer will occur. Incidence rates have been relatively stable since 1992. Death rates for ovarian cancer decreased by 2.0% per year from 2005 to 2009.For the general population of women, the lifetime risk of developing ovarian cancer is 1.39%; the lifetime risk of dying from ovarian cancer is 1.04%. Some women are at an increased risk due to an inherited susceptibility to ovarian cancer with the magnitude of that risk depending on the affected gene and specific mutation. Underlying ovarian cancer risk can be assessed through accurate pedigrees and/or genetic markers of risk. Because of uncertainties about cancer risks associated with specific gene mutations, genetic information may be difficult to interpret outside of families with a high incidence of ovarian cancer. Three inherited ovarian cancer susceptibility syndromes have been
Oophorectomy - About This PDQ Summary
About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current
Oophorectomy - General Information About Ovarian Germ Cell Tumors
Ovarian germ cell tumor is a disease in which malignant (cancer) cells form in the germ (egg) cells of the ovary. Germ cell tumors begin in the reproductive cells (egg or sperm) of the body. Ovarian germ cell tumors usually occur in teenage girls or young women and most often affect just one ovary. The ovaries are a pair of organs in the female reproductive system. They are located in the ...
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Cellular Classification of Ovarian Epithelial Cancer
The following is a list of ovarian epithelial cancer histologic classifications. Serous cystomas: Serous benign cystadenomas.Serous cystadenomas with proliferating activity of the epithelial cells and nuclear abnormalities but with no infiltrative destructive growth (low potential or borderline malignancy).Serous cystadenocarcinomas.Mucinous cystomas: Mucinous benign cystadenomas.Mucinous cystadenomas with proliferating activity of the epithelial cells and nuclear abnormalities but with no infiltrative destructive growth (low potential or borderline malignancy).Mucinous cystadenocarcinomas.Endometrioid tumors (similar to adenocarcinomas in the endometrium): Endometrioid benign cysts.Endometrioid tumors with proliferating activity of the epithelial cells and nuclear abnormalities but with no infiltrative destructive growth (low malignant potential or borderline malignancy).Endometrioid adenocarcinomas.Clear cell (mesonephroid) tumors: Benign clear cell tumors.Clear cell tumors with
Oophorectomy - Changes to This Summary (07 / 09 / 2012)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Stage Information for Ovarian Low Malignant Potential Tumors Updated staging information for 2010 (cited FIGO Committee on Gynecologic Oncology and Edge et al. as references 1 and 2, respectively).This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
Ovarian Germ Cell Tumors Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview
There are different types of treatment for patients with ovarian germ cell tumors. Different types of treatment are available for patients with ovarian germ cell tumor. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.Four types of standard treatment are used: SurgerySurgery is the most common treatment of ovarian germ cell tumor. A doctor may take out the cancer using one of the following types of surgery. Unilateral salpingo-oophorectomy: A surgical procedure to remove one ovary and one fallopian